Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan

INTRODUCTION: Teneligliptin/canagliflozin combination tablets, which combine a dipeptidyl peptidase-4 (DPP-4) inhibitor (teneligliptin) and a sodium-glucose cotransporter 2 (SGLT2) inhibitor (canagliflozin), are a treatment option for type 2 diabetes mellitus (T2DM) in Japan. This post-marketing sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadowaki, Takashi, Inagaki, Nobuya, Watada, Hirotaka, Sasaki, Kazuyo, Mori-Anai, Kazumi, Iwasaki, Tomohisa, Teranishi, Tatsuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989929/
https://www.ncbi.nlm.nih.gov/pubmed/35138572
http://dx.doi.org/10.1007/s12325-021-02038-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989929/
https://www.ncbi.nlm.nih.gov/pubmed/35138572
http://dx.doi.org/10.1007/s12325-021-02038-5

Ejemplares similares